Corporate Office:
Star 1, Opp IIM Bangalore, Bilekahalli,
Bannerghatta Road, Bengaluru –
560076, India
T: +91 80 6784 0738

Registered Office:
201, Devavrata, Sector 17, Vashi,
Navi Mumbai - 400 703, India
T: +91 22 2789 2924
F: +91 22 2789 2942

Date: April 10, 2025

BSE Limited **Listing Department-** **Phiroze Jeejeebhoy Towers** **Dalal Street** **Mumbai- 400001** **Scrip Code: 544292, ISIN: INE013P01021**	**National Stock Exchange of India Ltd** **Exchange Plaza, C-1, Block G,** **Bandra Kurla Complex,** **Bandra (E)** **Mumbai – 400 051** **Symbol: ONESOURCE**

Subject: **Intimation of Press Release as per SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

Enclosing the press release made by the Company w.r.t Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, for OneSource flagship Unit 2 facility, following a successful regulatory inspection from November 18, 2024 to November 22, 2024

The above information is also available on the website of the Company i.e. https://www.onesourcecdmo.com/investor-relations/stock-exchange-intimation/.

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Digitally signed by Trisha A
Date: 2025.04.10 11:19:06 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

onesource

Press Release
April 10,2025

OneSource Secures approval from Brazil for its flagship facility

Continues to maintain its exemplary track record in regulatory compliance and manufacturing quality.

Bangalore, India – April 10, 2025 – OneSource Specialty Pharma Limited today announced that its flagship Unit 2 facility in Bengaluru has been granted Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, following a successful regulatory inspection held in Nov 2024.

This approval marks a significant milestone in OneSource's ongoing commitment to quality and regulatory compliance. Unit 2 is OneSource's flagship site dedicated to manufacturing high quality Biologics drug substance and finished products including Drug Device Combinations (DDC) and other injectable products.

Neeraj Sharma, **CEO & Managing Director of OneSource**, commented: "We are proud to add ANVISA to the growing list of global regulatory agencies that have approved our flagship facility Unit 2 for its quality, compliance, and technical excellence. This approval now enables OneSource to supply pharmaceutical products specially DDCs, including GLP-1s manufactured at this site to the Brazilian market upon our customers getting their product approvals. It is a critical milestone for our company as Brazil is one of the biggest markets opening for generic Semaglutide in 2026."

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited), is India's first specialty pharma CDMO. OneSource Specialty Pharma operates five state-of-the-art facilities, all approved by major regulatory bodies, including the USFDA and EU authorities. Along with a team of over 1,200 professionals, including 200+ techno-commercial experts, we specialize in diverse dosage formats and advanced biologics platforms. Our comprehensive solutions span across Biologics, Drug-device combinations, Complex Injectables, and Oral Technologies. Committed to innovation and excellence, we support global customers in delivering life-saving products efficiently.

For further information, please contact:

Institutional Investors	**Corporate Communication**
Anurag Bhagania CFO Investor Relations Email: investor-relations@onesourcecdmo.com	**Pallavi Panchmatia:** +91 8951939181 **Abhilash Mukherjee:** +91 89044 28907 Email: corpcomm@onesourcecdmo.com **PR Consultancy** Adfactors PR **Janhavi Bellare**: +91 93228 54508 Email: Janhavi.bellare@adfactorspr.com **Syed Talal:** +91 99876 19679 Email: syed.talal@adfactorspr.com